1. A stable composition for intrathecal administration containing heparan-N-sulfatase protein (HNS), salt, buffering agent and polysorbate surfactant. A stable composition according to claim 1, characterized in that the HNS protein is present in a concentration of up to about 100 mg / ml. A stable composition according to claim 1, characterized in that the HNS protein is present in a concentration of up to about 30 mg / ml. A stable composition according to claim 1, characterized in that the HNS protein is present in a concentration from the range of about 10-20 mg / ml. A stable composition according to claim 1, characterized in that the HNS protein is present in a concentration in the range of about 15 mg / ml. The stable composition according to claim 1, characterized in that said protein contains the amino acid sequence of SEQ ID NO: 1.7. A stable composition according to any one of claims 1 to 6, characterized in that the salt is NaCl. 8. A stable composition according to claim 7, characterized in that NaCl is present in a concentration from a range of about 0-300 mM. A stable composition according to claim 8, characterized in that NaCl is present at a concentration of about 100-200 mm. A stable composition according to claim 9, characterized in that NaCl is present at a concentration of about 145 mM. A stable composition according to any one of claims 1 to 6, characterized in that the polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof. The stable composition according to claim 11, characterized in that the polysorbate surfactant is polysorbate 20.13. A stable composition according to claim 12, characterized in that polysorbate 20 is present in a concentration from a range of about 0-0.05%. Stable composition according to item 13, wherein the polysorbate 20 is present in to1. Стабильный состав для интратекального введения, содержащий белок гепаран-N-сульфатазы
